Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300110 | 0.86 | FDPS (0.56) | HPGDLMNAFDPSSMN1; SMN2ALDH1A1 | |
| SCHEMBL1300339 | 0.85 | HPGD (0.41) | HPGDALDH1A3LMNAFDPSSMN1; SMN2 | |
| SCHEMBL1299414 | 0.80 | HPGD (0.71) | HPGD | |
| SCHEMBL1299416 | 0.80 | HPGD (0.71) | HPGD | |
| SCHEMBL5448983 | 0.79 | FDPS (0.46) | HPGDALDH1A3LMNAFDPSSMN1; SMN2 | |
| SCHEMBL4177854 | 0.79 | HPGD (0.63) | HPGDALDH1A3FDPSALDH1A1 | |
| SCHEMBL5451218 | 0.75 | HPGD (0.59) | HPGDALDH1A3FDPSALDH1A1TSHR | |
| SCHEMBL3721435 | 0.74 | ALDH1A1 (0.62) | HPGDLMNAFDPSALDH1A1KDM4E | |
| SCHEMBL16272283 | 0.74 | ALDH1A3 (0.45) | HPGDALDH1A3ALDH1A1POLBTSHR | |
| SCHEMBL5451545 | 0.74 | HPGD (0.54) | HPGDALDH1A3FDPSALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383263-B1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | UNIV CHOSUN IACF (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-8637558-B2 | Thiazolidinedione derivative and use thereof | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY (KR) | 2014-01-28 | — | — | US | disclosed |
| US-20110269954-A1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY (KR) | 2011-11-03 | — | — | US | disclosed |
| EP-2383263-A2 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | Industry-academic Cooperation Foundation, Chosun University (KR) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269954-A1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | HPGD, CYP27B1, GCDH | HPGD 1/4885ALDH1A3 107/4885LMNA 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.